# Inotiv, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Inotiv, Inc.). ## Overview Inotiv, Inc. is a U.S.-based contract research organization that supports drug and medical device development from discovery through preclinical testing, and in some cases clinical phases. It also supplies research models, including animals and specialized diets, to pharmaceutical, medical device, academic, and government customers. ## Products & services • Nonclinical drug discovery and development services • Analytical and safety assessment studies • General toxicology, biotherapeutic, and medical device testing • Research models, including NHPs and rodent models • Research diets and related animal care services - **Discovery and Safety Assessment (DSA)** (45%) — Nonclinical and analytical research services that help advance drug and device candidates through discovery and preclinical testing. - **Research Models and Services (RMS)** (55%) — Supply of research animals, colony management, and related services used in preclinical studies. - Nonclinical drug discovery and development services - Analytical testing and safety assessment studies - General toxicology, biotherapeutic, and medical device services - Research models, including nonhuman primates and rodents - Research diets and animal care/welfare services ## Customers Inotiv sells primarily to pharmaceutical and medical device companies that need outsourced research capacity, specialized study design, and regulated preclinical execution. It also serves emerging biopharmaceutical firms, academia, and government clients that buy research models, diets, and testing services for R&D programs. Repeat business matters because customers’ needs rise and fall with research stage, while RMS customers often value continuity in animal supply and model consistency. - **Pharmaceutical and biopharmaceutical companies** (primary) — Buy toxicology, analytical, and discovery services to advance drug candidates through preclinical development. - **Medical device companies** (primary) — Buy safety assessment and related testing to support device development and regulatory submissions. - **Research models customers** (primary) — Buy nonhuman primates, rodents, and diets for in-house or outsourced studies, often valuing supply continuity. - **Emerging biopharmaceutical companies** (secondary) — Use flexible DSA services during discovery and early development when study needs change quickly. - **Academia and government** (secondary) — Purchase research animals and related products for scientific research and testing programs. - Pharmaceutical companies outsourcing nonclinical development work - Medical device firms needing safety and regulatory studies - Emerging biopharma clients with flexible study design needs - Academia and government buyers of research animals and diets - Repeat RMS customers seeking consistent animal models and supply ## Geography Inotiv is headquartered in West Lafayette, Indiana, and serves major research markets from North America and the U.K./Europe. The company disclosed that 12.7% of fiscal 2025 revenue came from facilities outside the U.S., so international operations are meaningful but not dominant. Its geographic footprint matters because client access, regulatory requirements, labor rules, and currency exposure differ across regions. - **United States** (87.3%) — Derived from disclosed 12.7% non-U.S. revenue in fiscal 2025. - **International** (12.7%) — Derived from disclosed 12.7% of revenue generated outside the U.S. in fiscal 2025. - Headquartered in West Lafayette, Indiana, United States - Commercial teams operate in North America and U.K./Europe - 12.7% of fiscal 2025 revenue came from outside the U.S. - International operations add currency, tax, and regulatory exposure - Global reach supports CRO clients and research-model distribution ## Strategy Management is focused on improving operating results through client service, margin discipline, and better capital allocation. The company is also trying to grow DSA contract awards and RMS product and service revenue while investing in animal welfare and capacity expansion to support future NHP colony management growth. - **Grow DSA study volume and contract awards** (short-term) — DSA is the higher-value service engine and broadens the company’s CRO offering. - **Expand RMS revenue and colony management capacity** (medium-term) — RMS provides recurring demand and benefits from customer preference for consistent models. - **Optimize capital allocation and expense base** (short-term) — The company is under pressure to improve margins and preserve liquidity. - Increase DSA contract awards and deepen scientific service mix - Grow RMS product and service revenue, especially NHP-related work - Invest in animal welfare and capacity expansion - Improve client service and operational execution - Optimize capital allocation and expense base ## Risks Inotiv faces a going-concern and covenant-compliance risk profile that can constrain financing and operating flexibility. Its business is also exposed to international operating risk, customer concentration and turnover tied to research cycles, and execution risk in animal-model supply and facility expansion. As a CRO and research-model provider, it is additionally exposed to pricing pressure, regulatory scrutiny, and demand swings in pharmaceutical R&D spending. - **Going-concern uncertainty** [critical] — Management disclosed substantial doubt about the company's ability to continue as a going concern. - **Debt covenant noncompliance** [critical] — The fiscal 2026 operating plan forecasts noncompliance with financial covenants under the Credit Agreement. - **International operating exposure** [high] — 12.7% of revenue came from outside the U.S., creating FX, tax, labor, and regulatory exposure. - **RMS pricing pressure** [high] — RMS revenue fell due primarily to lower pricing in connection with NHP sales. - **Client demand cyclicality** [medium] — Customer needs vary with research stage, causing turnover and uneven demand. - Going-concern uncertainty and potential debt covenant noncompliance - Need to refinance debt or raise capital on acceptable terms - International operations expose the company to FX and regulatory risk - RMS pricing pressure, especially in NHP product and service revenue - Client demand can fluctuate with research stage and funding cycles - Animal model supply requires biosecure facilities and strict operations ## Accounting Revenue recognition is important because Inotiv earns both service revenue and product revenue, and study timing can affect when revenue is recorded. Investors should also watch goodwill and intangible asset impairment, long-lived asset estimates, and contingencies, since the company has made acquisitions, is investing in facilities, and faces litigation and financing stress. Cash flow and debt-related accounting are especially important because non-cash charges, covenant compliance, and refinancing discussions can materially affect reported results and liquidity perception. - **Revenue recognition under ASC 606** — Can shift revenue between periods for DSA and RMS - **Goodwill and intangible assets** — Potential non-cash charges if performance weakens - **Long-lived asset estimates** — Depreciation and possible impairment charges - **Contingencies and litigation accruals** — Can materially affect expenses and liabilities - **Debt and covenant accounting** — May affect current/non-current debt presentation and going-concern assessment - ASC 606 revenue split between service and product revenue - Timing of study completion affects service revenue recognition - Goodwill and intangible asset impairment risk from acquisitions - Long-lived asset and facility investment estimates - Contingency and litigation accrual judgments - Debt and covenant disclosures affect liquidity assessment --- *Last updated: 2026-04-28T20:17:36.481789+00:00*